Jianing Xu1, Neil Gross2, Yuanwei Zang3, Shengda Cao1, Feilong Yang3, Zheng Yang4, Wenbin Yu5, Dapeng Lei1, Xinliang Pan6. 1. NHC Key Laboratory of Otorhinolaryngology, Department of Otorhinolaryngology, Qilu Hospital, Shandong University, Jinan, 250012, Shandong, China. 2. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. 3. Department of Urology,Qilu Hospital, Shandong University, Jinan, Shandong, 250012, China. 4. Key Laboratory of Otolaryngology Head and Neck Surgery, Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Beijing Institute of Otolaryngology, Ministry of Education, Capital Medical University, Beijing, 100730, China. 5. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Head and Neck Surgery, Peking University Cancer Hospital and Institute, Beijing, China. yuwenbin429@qq.com. 6. NHC Key Laboratory of Otorhinolaryngology, Department of Otorhinolaryngology, Qilu Hospital, Shandong University, Jinan, 250012, Shandong, China. panxinl915@126.com.
Abstract
INTRODUCTION: Hypopharyngeal squamous cell carcinoma (HSCC) is among the most lethal tumors encountered in the head and neck and frequently involves regional metastasis. However, the mechanism underlying the aggressiveness of HSCC remains elusive. S100A4 is a well-established metastasis-promoting regulator in a variety of malignancies, but its role in HSCC has not yet been identified. OBJECTIVES: Our objectives were to explore the expression levels of S100A4 in HSCC tumors and its association with clinicopathological parameters and the clinical prognosis of HSCC and to confirm its role in the metastatic process of the HSCC FaDu cell line in vitro. METHODS: We assessed the expression levels of S100A4 with immunohistochemistry (IHC) in HSCC tumors (n = 71) and adjacent normal tissues (n = 44). In vitro experiments were performed to explore the impact of S100A4 knockdown on biological phenotypes of human HSCC FaDu cell line, including migration, invasion, proliferation, apoptosis, and cell cycle. RESULTS: The expression of S100A4 was elevated in HSCC tumors compared with adjacent normal tissues and positively correlated with cervical lymph node metastasis in this HSCC patient cohort. In vitro experiments showed that S100A4 knockdown significantly impaired migration and invasion and increased the proportion of cells in G0/G1 phase with no change in proliferation or apoptosis in FaDu cells. Additionally, nuclear S100A4 expression proved to be an independent prognostic indicator in patients with HSCC. CONCLUSION: This study demonstrated for the first time that S100A4 expression is upregulated in HSCC tumors and that this upregulation is positively correlated with cervical lymph node metastasis of this malignancy. The metastasis-promoting role of S100A4 was further validated in the HSCC FaDu cell line, indicating that S100A4 is a potential therapeutic target for HSCC. Furthermore, this study suggests that nuclear S100A4 expression could be considered a prognostic biomarker for HSCC.
INTRODUCTION:Hypopharyngeal squamous cell carcinoma (HSCC) is among the most lethal tumors encountered in the head and neck and frequently involves regional metastasis. However, the mechanism underlying the aggressiveness of HSCC remains elusive. S100A4 is a well-established metastasis-promoting regulator in a variety of malignancies, but its role in HSCC has not yet been identified. OBJECTIVES: Our objectives were to explore the expression levels of S100A4 in HSCC tumors and its association with clinicopathological parameters and the clinical prognosis of HSCC and to confirm its role in the metastatic process of the HSCC FaDu cell line in vitro. METHODS: We assessed the expression levels of S100A4 with immunohistochemistry (IHC) in HSCC tumors (n = 71) and adjacent normal tissues (n = 44). In vitro experiments were performed to explore the impact of S100A4 knockdown on biological phenotypes of human HSCC FaDu cell line, including migration, invasion, proliferation, apoptosis, and cell cycle. RESULTS: The expression of S100A4 was elevated in HSCC tumors compared with adjacent normal tissues and positively correlated with cervical lymph node metastasis in this HSCC patient cohort. In vitro experiments showed that S100A4 knockdown significantly impaired migration and invasion and increased the proportion of cells in G0/G1 phase with no change in proliferation or apoptosis in FaDu cells. Additionally, nuclear S100A4 expression proved to be an independent prognostic indicator in patients with HSCC. CONCLUSION: This study demonstrated for the first time that S100A4 expression is upregulated in HSCC tumors and that this upregulation is positively correlated with cervical lymph node metastasis of this malignancy. The metastasis-promoting role of S100A4 was further validated in the HSCC FaDu cell line, indicating that S100A4 is a potential therapeutic target for HSCC. Furthermore, this study suggests that nuclear S100A4 expression could be considered a prognostic biomarker for HSCC.
Authors: G M Maelandsmo; E Hovig; M Skrede; O Engebraaten; V A Flørenes; O Myklebost; M Grigorian; E Lukanidin; K J Scanlon; O Fodstad Journal: Cancer Res Date: 1996-12-01 Impact factor: 12.701
Authors: N S Ambartsumian; M S Grigorian; I F Larsen; O Karlstrøm; N Sidenius; J Rygaard; G Georgiev; E Lukanidin Journal: Oncogene Date: 1996-10-17 Impact factor: 9.867
Authors: Robert P Takes; Primož Strojan; Carl E Silver; Patrick J Bradley; Missak Haigentz; Gregory T Wolf; Ashok R Shaha; Dana M Hartl; Jan Olofsson; Johannes A Langendijk; Alessandra Rinaldo; Alfio Ferlito Journal: Head Neck Date: 2010-11-10 Impact factor: 3.147
Authors: Kjetil Boye; Havjin Jacob; Kari-Anne M Frikstad; Jahn M Nesland; Gunhild M Maelandsmo; Olav Dahl; Arild Nesbakken; Kjersti Flatmark Journal: Cancer Med Date: 2016-06-08 Impact factor: 4.452